Target Name: MIR935
NCBI ID: G100126325
Review Report on MIR935 Target / Biomarker Content of Review Report on MIR935 Target / Biomarker
Other Name(s): mir-935 | MicroRNA 935 | MIRN935 | microRNA 935 | hsa-mir-935 | hsa-miR-935

MIR935 as a Promising Drug Target or Biomarker:

The advent of advanced technologies and the increasing understanding of the molecular mechanisms underlying various diseases have revolutionized the field of drug discovery and personalized medicine. One such molecular entity that has gained significant attention is MIR935, a small non-coding RNA molecule. MIR935 has shown great potential as both a drug target and a biomarker, holding promise for the development of innovative therapeutic strategies and precision medicine approaches. In this article, we will delve into the mechanisms, functions, and clinical significance of MIR935 in various diseases.

Understanding MIR935:

MIR935 belongs to the family of microRNAs (miRNAs), which are short RNA molecules that regulate gene expression. These non-coding RNA molecules do not code for proteins but instead bind to messenger RNA (mRNA) molecules, preventing them from being translated into proteins. By silencing specific mRNA molecules, miRNAs can finely tune gene expression, making them crucial regulators of various physiological and pathological processes.

MIR935 is specifically encoded by the MIR935 gene, which is located on a specific region of the genome. It has been identified in several species, including humans, mice, and rats. Research has shown that MIR935 is widely expressed in various tissues, and its levels can change in response to different stimuli or disease conditions.

MIR935 as a Drug Target:

One of the primary applications of MIR935 lies in its potential as a drug target. By targeting MIR935 with specific molecules, researchers aim to modulate its expression or function and consequently influence the expression of genes that contribute to disease pathology. Strategies such as small molecule inhibitors, antisense oligonucleotides, or gene editing techniques can potentially be employed to modify MIR935 levels or activity.

Through comprehensive research, scientists have implicated MIR935 in the pathogenesis of several diseases. For instance, in cancer, MIR935 has been found to be downregulated in certain tumor types, indicating a potential tumor suppressor role. By targeting and restoring MIR935 expression, it may be possible to inhibit tumor growth and progression. Similarly, MIR935 has also been associated with neurodegenerative disorders, cardiovascular diseases, and immune-related conditions, offering potential avenues for therapeutic intervention.

MIR935 as a Biomarker:

Apart from its potential as a therapeutic target, MIR935 also holds promise as a biomarker. Biomarkers are measurable indicators, which can be used to diagnose diseases, monitor the efficacy of therapeutic interventions, or predict patient outcomes. As MIR935 levels and expression patterns can change in response to various diseases or therapies, it has the potential to serve as a valuable biomarker in several clinical settings.

In cancer, for example, alterations in MIR935 levels have been observed in different tumor types and stages, suggesting its potential as a diagnostic or prognostic biomarker. By detecting and quantifying MIR935 levels in patient samples, clinicians may be able to assess disease progression, predict treatment response, and tailor therapies accordingly. Additionally, MIR935 has shown promise as a biomarker in other diseases, such as cardiovascular disorders and neurodegenerative conditions, further highlighting its versatility as a diagnostic tool.

Challenges and Future Directions:

While the potential of MIR935 as a drug target or biomarker is tantalizing, several challenges need to be addressed before its clinical translation. One significant hurdle lies in the development of efficient and specific delivery vehicles for therapeutic molecules targeting MIR935. Furthermore, the validation and standardization of methodologies for the detection and quantification of MIR935 in clinical samples are essential for its reliable use as a biomarker.

Looking ahead, ongoing research efforts are focused on elucidating the precise mechanisms underlying MIR935 regulation and its downstream effects on gene expression. A deeper understanding of MIR935's functional roles and interactions with other molecules will pave the way for the development of more specific and effective therapeutic interventions. Moreover, large-scale clinical studies are needed to validate the potential of MIR935 as a biomarker across different diseases and patient populations.

In conclusion, MIR935 represents a promising avenue in the fields of drug discovery and precision medicine. Through its roles as a drug target and biomarker, MIR935 offers exciting opportunities to develop novel therapeutic strategies and improve diagnostic capabilities. Continued research and collaboration among scientists, clinicians, and industry experts will ultimately determine the true clinical significance of MIR935 and drive its translation into beneficial applications for patients worldwide.

Protein Name: MicroRNA 935

The "MIR935 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR935 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex | Mitochondrial import inner membrane translocase 23 (TIM23) complex | Mitochondrial inner membrane protease complex | Mitochondrial membrane ATP synthase | Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) | Mitochondrial pyruvate carrier complex (MPC) | Mitochondrial RNA processing endoribonuclease | Mitofilin Complex | Mitofusin | Mitogen-Activated Protein Kinase | Mitogen-activated protein kinase (JNK) | Mitogen-Activated Protein Kinase (MAP Kinase)-Activated Protein Kinase | Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) | Mitogen-activated protein kinase p38 (MAPK p38) | MITRAC complex | MIX23 | MIXL1 | MKI67 | MKKS | MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1 | MKNK2 | MKRN1 | MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD